Immunotherapy, particularly blockade of the inhibitory receptor, PD-1 or the ligand; PD-L1, has shown effectiveness in a variety of cancers, but in many patients this effect remains of transient importance due to development of resistance. The gene discussed is CD274; the disease is cancer.